Richard Surosky
About Richard Surosky
Richard Surosky is a biotech professional known for his contributions to research on tau repression in the brain and gene editing in HIV-infected individuals. He has co-authored a publication focused on analytics for gene therapy manufacturing processes.
Work at Sangamo Therapeutics
Richard Surosky is a biotech professional associated with Sangamo Therapeutics. His work primarily focuses on innovative gene therapy solutions and gene editing technologies. He has contributed to significant research projects that aim to address complex neurological and viral diseases through advanced biotechnological methods.
Research Contributions
Richard Surosky has contributed to research on the persistent repression of tau in the brain. This research utilizes engineered zinc finger protein transcription factors, which are designed to target specific genes. His work in this area aims to enhance understanding of tau-related pathologies, which are implicated in neurodegenerative diseases.
Publications and Analytics in Gene Therapy
Richard Surosky co-authored a publication that outlines the analytics required to support a robust gene therapy manufacturing process. This publication emphasizes the importance of quality control and process optimization in gene therapy, providing insights that are critical for the advancement of therapeutic applications.
Gene Editing Research on HIV
Richard Surosky has been involved in a study focused on gene editing of CCR5 in autologous CD4 T cells of individuals infected with HIV. This research explores innovative approaches to modify immune cells, potentially improving treatment outcomes for HIV patients through targeted gene editing techniques.